The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity
COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal immunotherapy, based on a mixture of whole heat-inact...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/af5d6f5a1ddb4342b33ea0dcb74a03d1 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:af5d6f5a1ddb4342b33ea0dcb74a03d1 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:af5d6f5a1ddb4342b33ea0dcb74a03d12021-11-18T07:45:22ZThe Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity1664-322410.3389/fimmu.2021.748103https://doaj.org/article/af5d6f5a1ddb4342b33ea0dcb74a03d12021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.748103/fullhttps://doaj.org/toc/1664-3224COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal immunotherapy, based on a mixture of whole heat-inactivated bacteria, that has shown clinical efficacy against recurrent viral respiratory infections. Herein, we show that the prophylactic intranasal administration of this immunotherapy confers heterologous protection against SARS-CoV-2 infection in susceptible K18-hACE2 mice. Furthermore, in C57BL/6 mice, prophylactic administration of MV130 improves the immunogenicity of two different COVID-19 vaccine formulations targeting the SARS-CoV-2 spike (S) protein, inoculated either intramuscularly or intranasally. Independently of the vaccine candidate and vaccination route used, intranasal prophylaxis with MV130 boosted S-specific responses, including CD8+-T cell activation and the production of S-specific mucosal IgA antibodies. Therefore, the bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity.Carlos del FresnoCarlos del FresnoJuan García-ArriazaSarai Martínez-CanoSarai Martínez-CanoIgnacio Heras-MurilloAitor Jarit-CabanillasJoaquín Amores-IniestaPaola BrandiGillian DunphyCarmen Suay-CorrederaMaria Rosaria PricoloNatalia VicenteAndrés López-PerroteSofía CabezudoAna González-CorpasOscar LlorcaJorge Alegre-CebolladaUrtzi GaraigortaPablo GastaminzaMariano EstebanDavid SanchoFrontiers Media S.A.articleinnate immunityviral infectionspolybacterial mucosal immunotherapySARS-CoV-2vaccine immunogenicityImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
innate immunity viral infections polybacterial mucosal immunotherapy SARS-CoV-2 vaccine immunogenicity Immunologic diseases. Allergy RC581-607 |
| spellingShingle |
innate immunity viral infections polybacterial mucosal immunotherapy SARS-CoV-2 vaccine immunogenicity Immunologic diseases. Allergy RC581-607 Carlos del Fresno Carlos del Fresno Juan García-Arriaza Sarai Martínez-Cano Sarai Martínez-Cano Ignacio Heras-Murillo Aitor Jarit-Cabanillas Joaquín Amores-Iniesta Paola Brandi Gillian Dunphy Carmen Suay-Corredera Maria Rosaria Pricolo Natalia Vicente Andrés López-Perrote Sofía Cabezudo Ana González-Corpas Oscar Llorca Jorge Alegre-Cebollada Urtzi Garaigorta Pablo Gastaminza Mariano Esteban David Sancho The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity |
| description |
COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal immunotherapy, based on a mixture of whole heat-inactivated bacteria, that has shown clinical efficacy against recurrent viral respiratory infections. Herein, we show that the prophylactic intranasal administration of this immunotherapy confers heterologous protection against SARS-CoV-2 infection in susceptible K18-hACE2 mice. Furthermore, in C57BL/6 mice, prophylactic administration of MV130 improves the immunogenicity of two different COVID-19 vaccine formulations targeting the SARS-CoV-2 spike (S) protein, inoculated either intramuscularly or intranasally. Independently of the vaccine candidate and vaccination route used, intranasal prophylaxis with MV130 boosted S-specific responses, including CD8+-T cell activation and the production of S-specific mucosal IgA antibodies. Therefore, the bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity. |
| format |
article |
| author |
Carlos del Fresno Carlos del Fresno Juan García-Arriaza Sarai Martínez-Cano Sarai Martínez-Cano Ignacio Heras-Murillo Aitor Jarit-Cabanillas Joaquín Amores-Iniesta Paola Brandi Gillian Dunphy Carmen Suay-Corredera Maria Rosaria Pricolo Natalia Vicente Andrés López-Perrote Sofía Cabezudo Ana González-Corpas Oscar Llorca Jorge Alegre-Cebollada Urtzi Garaigorta Pablo Gastaminza Mariano Esteban David Sancho |
| author_facet |
Carlos del Fresno Carlos del Fresno Juan García-Arriaza Sarai Martínez-Cano Sarai Martínez-Cano Ignacio Heras-Murillo Aitor Jarit-Cabanillas Joaquín Amores-Iniesta Paola Brandi Gillian Dunphy Carmen Suay-Corredera Maria Rosaria Pricolo Natalia Vicente Andrés López-Perrote Sofía Cabezudo Ana González-Corpas Oscar Llorca Jorge Alegre-Cebollada Urtzi Garaigorta Pablo Gastaminza Mariano Esteban David Sancho |
| author_sort |
Carlos del Fresno |
| title |
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity |
| title_short |
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity |
| title_full |
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity |
| title_fullStr |
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity |
| title_full_unstemmed |
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity |
| title_sort |
bacterial mucosal immunotherapy mv130 protects against sars-cov-2 infection and improves covid-19 vaccines immunogenicity |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/af5d6f5a1ddb4342b33ea0dcb74a03d1 |
| work_keys_str_mv |
AT carlosdelfresno thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT carlosdelfresno thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT juangarciaarriaza thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT saraimartinezcano thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT saraimartinezcano thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT ignacioherasmurillo thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT aitorjaritcabanillas thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT joaquinamoresiniesta thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT paolabrandi thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT gilliandunphy thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT carmensuaycorredera thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT mariarosariapricolo thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT nataliavicente thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT andreslopezperrote thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT sofiacabezudo thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT anagonzalezcorpas thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT oscarllorca thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT jorgealegrecebollada thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT urtzigaraigorta thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT pablogastaminza thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT marianoesteban thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT davidsancho thebacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT carlosdelfresno bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT carlosdelfresno bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT juangarciaarriaza bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT saraimartinezcano bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT saraimartinezcano bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT ignacioherasmurillo bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT aitorjaritcabanillas bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT joaquinamoresiniesta bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT paolabrandi bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT gilliandunphy bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT carmensuaycorredera bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT mariarosariapricolo bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT nataliavicente bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT andreslopezperrote bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT sofiacabezudo bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT anagonzalezcorpas bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT oscarllorca bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT jorgealegrecebollada bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT urtzigaraigorta bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT pablogastaminza bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT marianoesteban bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity AT davidsancho bacterialmucosalimmunotherapymv130protectsagainstsarscov2infectionandimprovescovid19vaccinesimmunogenicity |
| _version_ |
1718422994896814080 |